Amgen is Still the King of the Biotech Sector

Amgen KRAS Inhibitor, Sotorasib
Amgen (AMGN) has taken on one of the toughest challenges in the last 40 years when it comes to cancer research by developing the KRAS inhibitor, sotorasib. This product was the first KRAS inhibitor to enter the clinic and is being studied in the broadest clinical program exploring 10 combinations with global sites spanning five continents.

In . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.